3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
11
Phase 3
1
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Motor Activity
9
Breast Neoplasms
7
Neoplasms
4
Fatigue
3
Recurrence
2
Body Weight
2
Weight Loss
1
Warts
1
Vomiting
1
Prostatic Neoplasms
1
Polycystic Ovary Syndrome
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Nausea
1
Multiple Myeloma
1
Lymphoma, Follicular
1
Lymphoma
1
Lung Neoplasms
1
Leukemia
1
Insulin Resistance
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Hematologic Diseases
1
Head and Neck Neoplasms
1
Dementia
1
Colonic Neoplasms
1
Cognitive Dysfunction
1
Asthenia
1
Anomia
1
Alzheimer Disease
1
Interventions
Paclitaxel
79
Carboplatin
64
Bevacizumab
33
liposomal doxorubicin
29
Topotecan
28
Gemcitabine
25
Cisplatin
19
olaparib
18
Drug Therapy
12
Doxorubicin
12
Taxes
11
niraparib
9
Docetaxel
6
CP protocol
6
Trabectedin
5
Hyperthermic Intraperitoneal Chemotherapy
5
Etoposide
5
Cyclophosphamide
5
1-dodecylpyridoxal
5
rucaparib
4
pembrolizumab
4
avelumab
4
atezolizumab
4
Immunoglobulin G
4
Ifosfamide
4
Disulfides
4
Dexamethasone
4
Chemotherapy, Adjuvant
4
trebananib
3
fluzoparib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Ovarian Neoplasms
×
Exercise
×
Clear all
NCT02107066
2018-04-20
WALC
Yale University
Phase 3
Completed
144 enrolled